公开(公告)号：US20250144172A1

公开(公告)日：2025-05-08

申请号：US19009000

申请日：2025-01-03

Applicant: The Texas A&M University System

Inventor： Richard H. Gomer ,  Darrell Pilling ,  Nehemiah Cox ,  Tejas R. Karhadkar

IPC: A61K38/17 ,  A61K9/00 ,  A61K31/196 ,  A61K31/215 ,  A61K31/351 ,  A61K31/4192 ,  A61K31/495 ,  A61P11/00 ,  A61P19/04 ,  C07K16/40

Abstract: The present disclosure relates to anti-fibrotic sialidase-inhibitor compounds and methods of preventing or inhibiting fibrosis using such compounds. The present disclosure also relates to methods of controlling the formation of fibrocytes or their activity using such compounds. The compounds may include both antibodies as well as small molecules. The methods may involve administering the compounds to a patient with or at risk of developing fibrosis in a manner that inhibits at least one sialidase in the patient.

公开(公告)号：US20220133671A1

公开(公告)日：2022-05-05

申请号：US17430287

申请日：2020-02-10

Applicant: The Texas A&M University System

Inventor： Richard H. Gomer ,  Thomas Meek ,  Tejas Karhadkar ,  Darrell Pilling

IPC: A61K31/215 ,  A61P35/00 ,  A61K31/351 ,  A61K31/401 ,  A61K31/4406 ,  A61K31/4402 ,  A61K31/4422 ,  A61K31/445 ,  A61K31/455 ,  A61K31/55 ,  A61K31/60

Abstract: The present disclosure relates to methods of preventing or inhibiting fibrosis using small molecule sialidase inhibitors. The present disclosure also relates to methods treating obesity, liver inflammation, steatosis, and cancer. These methods can involve administering the compounds to a patent at risk of developing fibrosis inflammation, obesity, steatosis, or cancer, in a manner that inhibits NEU3.

公开(公告)号：US20190201485A1

公开(公告)日：2019-07-04

申请号：US16293379

申请日：2019-03-05

Applicant: The Texas A&M University System

Inventor： Richard H. Gomer ,  Darrell Pilling ,  Nehemiah Cox ,  Tejas R. Karhadkar

IPC: A61K38/17 ,  A61K9/00 ,  A61K31/351 ,  A61P19/04 ,  A61K31/4192 ,  A61K31/495

CPC classification number: A61K38/177 ,  A61K9/0019 ,  A61K31/196 ,  A61K31/215 ,  A61K31/351 ,  A61K31/4192 ,  A61K31/495 ,  A61P11/00 ,  A61P19/04 ,  C07K16/40 ,  Y02A50/401

Abstract: The present disclosure relates to anti-fibrotic sialidase-inhibitor compounds and methods of preventing or inhibiting fibrosis using such compounds. The present disclosure also relates to methods of controlling the formation of fibrocytes or their activity using such compounds. The compounds may include both antibodies as well as small molecules. The methods may involve administering the compounds to a patient with or at risk of developing fibrosis in a manner that inhibits at least one sialidase in the patient.